Last edition
News about "Clinical Trials"
Genprex Partners with US CDMO to Scale Up Diabetes Gene Therapy Manufacturing
Genprex has partnered with a US-based CDMO to scale up cGMP manufacturing of its AAV-based diabetes gene therapy candidate, supporting IND-enabling studies and future clinical trials.
Clinical Trials. | 19/08/2026 | By News Bureau
Chugai Files for Expanded Tecentriq Use in MSI-High Colon Cancer in Japan
Chugai Pharmaceutical has filed a Japanese regulatory application seeking an expanded Tecentriq indication for adjuvant treatment of MSI-High colon cancer. The filing is backed by Phase 3 ATOMIC data showing three-year disease-free survival of 86.3 percent with Tecentriq plus mFOLFOX6, versus 76.2 percent with chemotherapy alone.
Clinical Trials | 17/08/2026 | By News Bureau
Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.
Clinical Trials | 04/08/2026 | By News Bureau
UK Life Sciences Attracts Investment to Create Jobs and Faster Patient Treatments
The UK life sciences sector has attracted over £3 billion in public-private investment in the past year, accelerating innovation, creating jobs, and improving patient access to new treatments.
Clinical Trials | 10/07/2026 | By News Bureau
Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome
Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.
Clinical Trials | 06/07/2026 | By Akanki | 241
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Clinical Trials | 26/06/2026 | By News Bureau | 192
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
Clinical Trials | 23/06/2026 | By News Bureau | 206
Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.
Clinical Trials | 22/06/2026 | By News Bureau | 162
Australia Approves MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) with rituximab and lenalidomide, the first chemo-free dual-targeted therapy for relapsed follicular lymphoma.
Clinical Trials | 24/04/2026 | By News Bureau
Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer
Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.
Clinical Trials | 23/04/2026 | By News Bureau | 205
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy